18 Apr 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Members of the board and management exercise warrants and subscribe for shares in FluoGuide A/S

Press release

April 29, 2020

FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that board members and management have exercised all of their respective warrants of series TO1. In total this means that 112,322 warrants are to be converted, corresponding to a total investment of approximately DKK 668,000. In total, investments from the Board and Management correspond to approximately 10.5 percent of the total outstanding warrants of series TO1.

The FluoGuide warrants of series TO 1 that was issued in connection with FluoGuide’s issue of units, prior to listing on Spotlight Stock Market. The exercise period for the warrants TO 1 runs until and including 7 May 2020. Upon full exercise of all warrants of series TO 1, FluoGuide will be allocated approximately DKK 6.4 million (before costs). FluoGuide hereby announces that board members and management have chosen to exercise 112,322 warrants to subscribe for a total of 112,322 new shares in the Company. Below, each person’s amount of exercised warrants of series TO 1 is presented: Arne Ferstad (Member of the Board): 44,929 warrants; Grethe Nørskov Rasmussen (Chief Development Officer): 44,929 warrants; Peter Mørch Eriksen (Member of the Board): 18,720 warrants; and Micaela Sjökvist (Member of the Board): 3,744 warrants.


For further information regarding the warrants of series TO 1, please contact:
Sedermera Fondkommission
+46 40 – 615 14 10